scispace - formally typeset
Journal ArticleDOI

Simultaneous Delivery of siRNA and Paclitaxel via a “Two-in-One” Micelleplex Promotes Synergistic Tumor Suppression

Reads0
Chats0
TLDR
Clear evidence is shown that the micelleplex is capable of delivering siRNA and paclitaxel simultaneously to the same tumoral cells both in vitro and in vivo and can induce a synergistic tumor suppression effect in the MDA-MB-435s xenograft murine model.
Abstract
Combination of two or more therapeutic strategies with different mechanisms can cooperatively prohibit cancer development. Combination of chemotherapy and small interfering RNA (siRNA)-based therapy represents an example of this approach. Hypothesizing that the chemotherapeutic drug and the siRNA should be simultaneously delivered to the same tumoral cell to exert their synergistic effect, the development of delivery systems that can efficiently encapsulate two drugs and successfully deliver payloads to targeted sites via systemic administration has proven to be challenging. Here, we demonstrate an innovative “two-in-one” micelleplex approach based on micellar nanoparticles of a biodegradable triblock copolymer poly(ethylene glycol)-b-poly(e-caprolactone)-b-poly(2-aminoethyl ethylene phosphate) to systemically deliver the siRNA and chemotherapeutic drug. We show clear evidence that the micelleplex is capable of delivering siRNA and paclitaxel simultaneously to the same tumoral cells both in vitro and in v...

read more

Citations
More filters
Journal ArticleDOI

Engineered Nanoparticles for Drug Delivery in Cancer Therapy

TL;DR: It is anticipated that precisely engineered nanoparticles will emerge as the next-generation platform for cancer therapy and many other biomedical applications.
Journal ArticleDOI

Nanotechnology for Multimodal Synergistic Cancer Therapy

TL;DR: In this review, state-of-the-art studies concerning recent advances in nanotechnology-mediated multimodal synergistic therapy will be systematically discussed, with an emphasis on the construction of multifunctional nanomaterials for realizing bimodal and trimodal synergy therapy.
Journal ArticleDOI

Advanced materials and processing for drug delivery: The past and the future

TL;DR: In this review, this review focuses on the materials innovation and processing of drug delivery systems and how these advances have shaped the past and may influence the future of drug Delivery.
Journal ArticleDOI

Single-Step Assembly of DOX/ICG Loaded Lipid–Polymer Nanoparticles for Highly Effective Chemo-photothermal Combination Therapy

TL;DR: The well-defined DINPs exhibited great potential in targeting cancer imaging and chemo-photothermal therapy and no tumor recurrence was observed after only a single dose of DINP with laser irradiation.
Journal ArticleDOI

Codelivery of an Optimal Drug/siRNA Combination Using Mesoporous Silica Nanoparticles To Overcome Drug Resistance in Breast Cancer in Vitro and in Vivo

TL;DR: Proof-of-principle testing of the use of a dual drug/siRNA nanocarrier to overcome Dox resistance in a xenograft is provided and the first detailed analysis of the impact of heterogeneity in the tumor microenvironment on the efficacy of siRNA delivery in vivo is provided.
References
More filters
Journal ArticleDOI

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

TL;DR: A generalized method for analyzing the effects of multiple drugs and for determining summation, synergism and antagonism has been proposed and has been used to analyze experimental data obtained from enzymatic, cellular and animal systems.
Journal Article

A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs

TL;DR: It is speculated that the tumoritropic accumulation of smancs and other proteins resulted because of the hypervasculature, an enhanced permeability to even macromolecules, and little recovery through either blood vessels or lymphatic vessels in tumors of tumor-bearing mice.
Journal ArticleDOI

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

TL;DR: Evidence is provided of inducing an RNAi mechanism of action in a human from the delivered siRNA and the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for anRNAi mechanism from a patient who received the highest dose of the nanoparticles.
Related Papers (5)